Every 424B that Nanoviricides (NNVC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NNVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NNVC filings page.
NanoViricides, Inc. (NNVC) has filed a resale prospectus covering up to 2,516,339 shares of common stock issuable upon exercise of outstanding common stock purchase warrants held by a selling stockholder. The warrants have an exercise price of $1.75 per share and were issued in a July 24, 2026 registered direct offering.
The company is not selling any shares in this prospectus and will not receive proceeds from resales by the selling stockholder. NanoViricides would receive up to approximately $4.4 million in gross proceeds only if all common warrants are exercised for cash, which may or may not occur. As of August 21, 2026, there were 25,527,353 shares of common stock outstanding, which would rise to 28,043,692 shares assuming full warrant exercise. The company has no products or revenues, is a clinical-stage antiviral drug developer with lead candidate NV-387 ready for Phase II trials, and its common stock trades on NYSE American under the symbol NNVC at a last reported price of $1.34 on August 19, 2026.
NanoViricides, Inc. is conducting a registered direct offering of 2,416,339 shares of common stock at $1.53 per share and Pre-Funded Warrants to purchase up to 100,000 shares at $1.52999 each, together with Common Warrants to purchase up to 2,516,339 shares at an exercise price of $1.75 per share. Each Pre-Funded Warrant is immediately exercisable at $0.00001 per share; each Common Warrant becomes exercisable six months after issuance and expires five and one-half years from issuance.
Gross proceeds are expected to be $3,849,997.67, with a 7.0% placement fee of $269,499.91, yielding approximately $3,580,497.76 before other expenses and about $3,450,000 in estimated net proceeds. The company plans to use the funds for general corporate purposes, including working capital, capital expenditures, research and development, clinical trials, and potential acquisitions or other strategic purposes. Common stock outstanding is expected to increase to 25,499,155 shares after the offering, assuming exercise of the Pre-Funded Warrants but excluding the Common Warrants.
NanoViricides is a clinical-stage company with no approved products or revenues, significant accumulated losses, and a disclosed cash position that, together with other resources, does not fund at least 12 months of planned operations, leading management to state there is substantial doubt about its ability to continue as a going concern without additional financing.
NanoViricides, Inc. has amended its prospectus supplement for its at-the-market common stock offering program to reduce the maximum amount it may sell under its existing Form S-3 registration to $0 of common stock. This change reflects limits under General Instruction I.B.6 of Form S-3.
As of July 23, 2026, the company’s public float was $41,583,701, based on 22,356,829 non-affiliate shares at $1.86 per share, and it has sold approximately $9,843,165 of common stock under I.B.6 in the prior 12-month period. Under the amended terms, NanoViricides may not currently offer or sell additional shares through or to D. Boral Capital LLC under the At Market Issuance Sales Agreement. If its public float changes, the company may again conduct primary offerings on Form S-3 up to one-third of its public float, and if its public float rises above $75 million, the I.B.6 limitation would no longer apply.
NanoViricides, Inc. is undertaking an at‑the‑market offering of up to $4,018,069 of common stock under a Sales Agreement with D. Boral Capital LLC, which will act as sales agent or principal and receive a 2% commission on gross sales.
The company may sell shares from time to time on NYSE American or other permitted markets, with no minimum sale amount and no escrow. An illustrative case assumes issuance of 2,660,973 shares at $1.51 per share, increasing shares outstanding from 22,982,816 to up to 25,643,789, causing immediate dilution of about $0.99 per share versus the assumed offering price.
As of July 10, 2026, public float was about $41,583,701 (22,356,829 non‑affiliate shares at $1.86). The company has sold approximately $9,843,165 of common stock under Form S‑3 General Instruction I.B.6 in the prior 12 months and is subject to the one‑third‑of‑float cap for primary offerings while float remains below $75 million. Net proceeds will be used for general corporate purposes, including working capital, R&D and clinical trial spending.
NanoViricides, Inc. registers for resale up to 1,333,334 shares of Common Stock issuable upon exercise of Common Stock Purchase Warrants issued in a registered direct offering. The Company will not receive proceeds from resales by the Selling Stockholder; if the Common Warrants are exercised for cash, the Company would receive approximately $2.33 million.
The prospectus lists 22,982,816 shares outstanding as of June 4, 2026 and describes the Offering structure (1,133,334 common shares, 200,000 pre-funded warrants and 1,333,334 Common Warrants issued May 15, 2026). The Selling Stockholder named is Orca Capital AG, which may offer shares at varied prices and by multiple methods; discounts and selling commissions will be borne by the Selling Stockholder.
NanoViricides, Inc. is conducting a registered direct offering of 1,333,334 shares of Common Stock, pre-funded warrants to purchase up to 200,000 shares and common warrants to purchase up to 1,333,334 shares at stated prices. The shares are offered at $1.50 per share, pre-funded warrants at $1.49999 each and common warrants exercisable at $1.75. Net proceeds to the company are expected to be approximately $1.735M, and delivery is expected on or about May 18, 2026. The prospectus supplement notes 22,780,334 shares outstanding immediately after the Offering and discloses a going-concern qualification tied to cash needs and anticipated future financings.
NanoViricides, Inc. is registering up to 7,142,858 shares of common stock for resale by a single selling stockholder. These shares are issuable upon exercise of Series A warrants for 3,571,429 shares at $1.75 per share and Series B warrants for 3,571,429 shares at $2.00 per share, all originally issued in a November 10, 2025 private placement. The company will not receive any proceeds from the resale of these shares, but could receive up to approximately $13.4 million in gross proceeds if all the warrants are exercised for cash.
NanoViricides is a clinical-stage company developing antiviral drugs based on its nanoviricides platform. Lead candidate NV-387 has completed a Phase Ia/Ib safety trial with no reportable adverse events and is being advanced toward Phase II trials for MPox and viral acute and severe-acute respiratory infections. As of mid‑December 2025, 21,568,429 shares of common stock were outstanding, with additional preferred shares and warrants reserved for future issuance.
NanoViricides, Inc. launched a registered direct offering of 1,970,000 shares of common stock at $1.68 per share and pre-funded warrants to purchase up to 1,601,429 shares at $1.67999 per pre-funded warrant. This filing also covers 1,601,429 shares issuable upon exercise of those pre-funded warrants at an exercise price of $0.00001 per share, which are immediately exercisable.
The offering size is $6,000,000 in gross proceeds, with a 7% placement fee of $420,000; the company expects approximately $5,505,000 in net proceeds, earmarked for general corporate purposes including working capital, R&D and clinical trial expenditures. A.G.P./Alliance Global Partners is acting as exclusive placement agent on a reasonable best efforts basis.
In a concurrent private placement, the company is selling Series A warrants to purchase up to 3,571,429 shares at $1.75 (exercisable beginning six months for 18 months) and Series B warrants to purchase up to 3,571,429 shares at $2.00 (exercisable beginning six months for five years); these PIPE securities are not registered here. Shares outstanding were 18,006,532 immediately after the offering, as of November 10, 2025.
NanoViricides, Inc. filed Amendment No. 2 to its prospectus supplement for its at-the-market offering, updating the maximum amount available to sell to $0 under its Form S-3 program with D. Boral Capital LLC (formerly EF Hutton) as agent.
The company states it may not currently offer and sell common stock through or to the agent pursuant to the prospectus as amended. This update reflects the Form S-3 General Instruction I.B.6 limitations tied to public float. As of November 10, 2025, public float was $34,719,086, based on 17,359,543 non‑affiliate shares at $2.00 per share. Over the prior 12 months, the company has offered and sold approximately $5,009,140 of common stock under I.B.6.
The company notes that if its public float changes, it may sell up to one‑third of its public float on Form S‑3, subject to the Sales Agreement, and that the I.B.6 cap no longer applies if public float exceeds $75 million.